1. 2864 Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial. (September 2015) Authors: Kiyota, N.; Robinson, B.; Shah, M.; Hoff, A.O.; Taylor, M.; Li, D.; Dutcus, C.; Lee, E.K.; Kim, S.B.; Tahara, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗